Antibiotics for ventilator-associated pneumonia.

Area of Science:

• Critical Care Medicine
• Infectious Diseases
• Pharmacology

Background:

• Ventilator-associated pneumonia (VAP) is a serious complication of mechanical ventilation, associated with significant morbidity and mortality.
• Current treatment guidelines for VAP recommend empirical antibiotic therapy based on resistance risk, but evidence quality is limited.
• Inappropriate initial antibiotic treatment for VAP is linked to increased mortality and longer intensive care unit (ICU) stays.

Purpose of the Study:

• To assess the impact of different empirical antimicrobial therapies on survival and clinical cure in adult VAP patients.
• To report on adverse events, superinfections, and hospital/ICU length of stay associated with VAP treatments.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs) comparing empirical antibiotic regimens for VAP.
• Searched multiple databases (CENTRAL, MEDLINE, Embase, etc.) up to September 2016.
• Analyzed data comparing monotherapy vs. combination therapy and carbapenem vs. non-carbapenem therapies.

Main Results:

• No significant difference in all-cause mortality, clinical cure, ICU length of stay, or adverse events between monotherapy and combination therapy.
• Carbapenem therapy showed a statistically significant increase in clinical cure rates compared to non-carbapenem therapies.
• Evidence quality for mortality and clinical cure in the carbapenem comparison was downgraded to moderate.

Conclusions:

• Monotherapy and combination therapy showed similar outcomes for VAP treatment.
• Carbapenems may be associated with improved clinical cure rates in VAP.
• Further research is needed to determine optimal antibiotic choices for VAP, especially in patients at risk for multidrug-resistant bacteria.